Proximus harnesses ADVA synchronization solution for 5G network timing
23.3.2021 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Proximus is leveraging its Oscilloquartz timing technology to synchronize Belgium’s largest open mobile network. The deployment enables Proximus to improve speed, coverage and reliability for millions of mobile users throughout Belgium, while also preparing its network for next-generation services. By deploying ADVA’s core grandmaster devices, access boundary clocks and its enhanced primary reference time clock (ePRTC) solution, the country’s incumbent telecommunications service provider is ensuring the levels of timing accuracy and resilience needed for 5G, broadcast and other time-sensitive services. The technology was implemented by ADVA’s partner Arcadiz Telecom, a leading provider of connectivity solutions across the Benelux region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323005060/en/
ADVA’s timing technology is an integral part of Proximus’s 5G strategy (Photo: Business Wire)
“By harnessing ADVA’s network timing innovation, we’re ensuring unprecedented levels of precision and reliability. This deployment is a core component of our 5G strategy. It means more value not only for our customers looking to access data-intensive applications and stream high-quality video wherever they are, but also for telco operators using our open network,” said Patrick Delcoigne, director, network engineering and operations, Proximus. “ADVA’s grandmaster clock and ePRC cesium technology empower us to meet key timing challenges. It enables highly accurate phase precision, enhanced stability and long-term protection from GNSS outages. Just as important, though, is the support of the ADVA and Arcadiz Telecom team. Their engineers have worked closely with us to ensure that the network meets all of our requirements.”
Proximus’s new nationwide synchronization network is built on the OSA 5440, an ultra-stable timing solution optimized for deployment in core networks and the OSA 5412 family of cost-effective, mid-scale synchronization devices engineered for deployment in a wide range of locations. It’s anchored by the robust and proven OSA 3230B ePRC cesium clock installed in two central sites. This supports high levels of frequency stability compliant with the strictest ITU-T standards and, combined with the OSA 5440, ensures long-term stability of UTC time. The extended stability performance of ADVA’s ePRC provides immunity against GNSS outages – a crucial requirement for mission-critical applications that should not rely on satellite-based timing alone.
“For major mobile network operators like Proximus, our PTP grandmaster and boundary clocks and our ePRTC solution are the perfect tools. They enhance overall performance and deliver the precision timing necessary for 5G use cases. Our technology also enables other services such as broadcast networks to migrate to IP-based timing,” commented Jörg Urban, senior director, business development, Oscilloquartz, ADVA. “The OSA 5412 Series and OSA 5440 support a smooth and cost-effective migration to next-generation phase and frequency synchronization. And with our ePRTC solution providing robust backup for GNSS, Proximus’ mobile customers can be sure of high-quality, uninterrupted services with no loss of performance.”
“At Arcadiz Telecom, we know what it takes to build a network ready to support tomorrow’s services. With ADVA’s Oscilloquartz timing technology and the ongoing support and maintenance of our team, Proximus can be confident that its synchronization infrastructure delivers for today’s needs while being fully equipped for the future,” said Marc Vandeputte, CTO, Arcadiz Telecom. “When it comes to 5G connectivity, every nanosecond counts. That’s why the stringent accuracy and stability of ADVA’s technology is so important. It empowers Proximus to deliver enhanced speeds, coverage and quality to its mobile users. For Belgians, this deployment will enable a wide range of new experiences from instant access to video streams to immersive AR and VR experiences.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we’re creating new opportunities for tomorrow’s networks. For more information, please visit us at www.oscilloquartz.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005060/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
